Corcept Therapeutics Incorporated (CORT)

NASDAQ

$87.30

-$0.69 (0.78%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$87.11$89.00

Open $88.74

52 Week Range

$49.00$117.33

Previous Close $87.99

Market Cap9.18B

Volume799.15K

Avg Volume850.66K

P/E (TTM)85.94

EPS (TTM)$1.02

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Corcept Therapeutics Incorporated

NOV42025

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

Source: Business Wire•41 days ago

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders ...

OCT282025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Source: Business Wire•48 days ago

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call th...

OCT192025

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Source: Business Wire•58 days ago

OCT142025

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Source: Business Wire•63 days ago

OCT12025

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

Source: Business Wire•76 days ago

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients an...

SEP222025

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Source: Business Wire•84 days ago